Lenmed Health Management Pty Ltd has acquired Daxina Medical Center (DMC)
Lenmed Health Pty Ltd, through its subsidiary Lenmed Health Management Pty Ltd. (Lenmed Health), has acquired the business assets of Daxina Medical Center (DMC), comprising the hospital land and buildings and all other assets and operations of the hospital, including the pharmacy assets and operations located on the land from which DMC conducts its hospital activities, for US$5.5 million.
Lenmed Health is an established hospital group in South Africa, operating multi-specialty hospital facilities in South Africa, Mozambique and Botswana, managing more than 1,300 beds.
DMC is a 100% private hospital located south of Johannesburg to serve the communities of Lenasia South, Orange Farm, Ennerdale, Evaton, Sebokeng and Vereeniging.
Oaklins' team in South Africa acted as corporate and financial advisor to the buyer in this transaction.
Talk to the deal team
Related deals
Lindenhofgruppe has sold its majority stake in LabPoint to Affidea Switzerland
LabPoint Medical Laboratories AG has been acquired by Affidea Switzerland AG. Through the transaction, Lindenhofgruppe AG gains a strong strategic partner to support the further development of LabPoint and will remain a shareholder with a reduced stake, continuing as a key customer of the company. It lays the foundation for LabPoint’s sustainable development under a new anchor shareholder, with the aim of further strengthening and selectively expanding its position in laboratory diagnostics.
Learn moreEuroHospital Varna has been acquired by Intermedica Group
EuroHospital Varna has been acquired by Intermedica Group, allowing the business to continue to grow and deliver high-quality healthcare services to its patients. Through the transaction, Intermedica Group expands its healthcare presence and intends to build a new model of integrated personalized care focused on preventive, holistic and digital medicine.
Learn moreOlyos Group has acquired a controlling stake in NewScience
Olyos Group has acquired a controlling stake in NewScience from its founders through a transaction structured in two stages, with the strategic objective of ultimately acquiring 100% of the company. The transaction forms part of NewScience’s international growth strategy and a gradual cash-out process for the founder, who intends to complete a full exit. Olyos intends to retain the management team through a put and call option mechanism and an earn-out linked to NewScience’s 2025 EBITDA.
Learn more